- Iomab-B is currently being studied in the SIERRA clinical trial. It is an investigational drug (not approved by the FDA) that targets bone marrow and cancer (leukemia) cells. It is used to help patients get ready for bone marrow transplant (BMT) also known as hematopoietic stem cell transplantation (HCT). A bone marrow transplant remains the only potentially curative option in this population.
- Iomab-B is a targeted therapy, a monoclonal antibody that is connected to radioactive material (making it a radiolabeled antibody). Iomab-B delivers radiation selectively to your bone marrow and spleen, where most leukemia cells are, when compared to other organs such as liver, lungs, kidneys and mucous membranes that can be harmed by too much radiation.
- Iomab-B was initially developed at the Fred Hutchinson Cancer Research Center in Seattle, WA. Previous studies of Iomab-B at that institution showed promise, when Iomab-B was used as part of the preparation for a bone marrow transplant.
- Iomab-B may allow some patients with Acute Myeloid Leukemia to get a bone marrow transplant.